NCT05124561View on ClinicalTrials.gov

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 15, 2021

Primary Completion Date

April 15, 2022

Study Completion Date

August 20, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)

Nebulized inhalation through the mouth

BIOLOGICAL

Placebo

Nebulized inhalation through the mouth

Sponsors
All Listed Sponsors
collaborator

Beijing Institute of Biotechnology

OTHER

lead

CanSino Biologics Inc.

INDUSTRY

NCT05124561 - Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) | Biotech Hunter | Biotech Hunter